Realising the promised gains of cardiovascular innovation will demand an increase in clinical cardiac decision-making capacity
Modern cardiovascular care has been blessed with therapeutic innovations that have reduced morbidity and mortality. From invasive management for acute coronary syndrome (ACS) to nurse-led heart failure management programs and anticoagulation for stroke prophylaxis in atrial fibrillation (AF), therapeutic advances have led not only to improved cardiovascular outcomes, but also the need for greater sophistication in balancing benefits with harms and costs (Box). With such complexity, decisions about management increasingly require access to risk stratification and evidence-based clinical decision support.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
No relevant disclosures.